当前位置: 首页 >> 检索结果
41. Mapping the future: identifying research priorities in rheumatoid arthritis with the James Lind Alliance approach.
作者: Kristine Røren Nordén.;Anna Fryxelius.;Ingrid Fjeldheim Bånerud.;Gunnstein Bakland.;Tore Voksø.;Mona Larsen.;Astrid Torgersen Lunestad.;Kjersti Storheim.;Amy Martinsen.;Rikke Munk Killingmo.
来源: BMC Rheumatol. 2025年9卷1期133页
Considerable knowledge gaps remain regarding the cause, prevention, and management of rheumatoid arthritis (RA), with limited systematic effort to establish research priorities that truly align with the preferences of those impacted by RA.
42. TNF-α inhibitor etanercept improves cerebrovascular function in elderly RA patients: findings from a randomized controlled trial.
作者: Qiao-Qiao Ren.;Pei Chen.;Lin Qiao.;Yong-Ku Du.;Rui-Song Wang.;Xiao-Qiang Huang.;Hua Guo.;Jun Yan.
来源: BMC Rheumatol. 2025年9卷1期135页
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease that can affect the cardiovascular and cerebrovascular systems. Elderly RA patients face a significantly elevated risk of cerebrovascular events, the core mechanism of which may be related to chronic inflammation-mediated vascular endothelial dysfunction and impaired cerebral blood flow regulation. Tumor necrosis factor-alpha (TNF-α) is a key pro-inflammatory cytokine in RA, yet whether its inhibitor can improve cerebral hemodynamics remains unclear. This study aims to investigate the effects and underlying mechanisms of TNF-α inhibitor etanercept on cerebral blood flow in elderly RA patients.
43. Elevated levels of serum angiopoietin-1, IL-17, osteopontin, and CXCL-9 as markers of vascular inflammation in newly-diagnosed PMR.
作者: Sharon Cowley.;Patricia Harkins.;Thomas J Butler.;Colm Kirby.;Danielle Molloy.;Richard Conway.;David Kane.
来源: Rheumatology (Oxford). 2025年
GCA and PMR are commonly overlapping diseases. Biomarkers for detecting vascular inflammation in PMR patients are lacking. We aimed to determine the diagnostic value of serum levels of angiopoietin-1, angiopoietin-2, interleukin-6, interleukin-17A, interleukin-23, CXCL-9, and osteopontin (OPN) in identifying vascular inflammation in PMR.
45. Machine learning for predicting treatment response to biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a scoping review.
作者: Ehiremen Bennard Eriakha.;Yu Han.;Mai Li.;Jieni Li.;Yinan Huang.
来源: BMC Rheumatol. 2025年9卷1期132页
Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have improved outcomes in rheumatoid arthritis (RA). However, heterogeneity in treatment response remains a significant challenge. Machine learning (ML) may enable improved prediction, but the comprehensive review of ML applications in RA is fragmented and limited. This scoping review synthesizes the literature on ML methods for predicting treatment response to b/tsDMARDs in RA.
46. Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS).
作者: Eric F Morand.;Richard Furie.;Martin Aringer.;Laurent Arnaud.;Christine Peschken.;Alberta Hoi.;Kai Wai Lee.;Jonatan Hedberg.;Tina Grünfeld Eén.;Raj Tummala.;Stephanie Chen.;Bo Ding.
来源: Rheumatology (Oxford). 2025年
We describe disease progression in patients from the SLE Prospective Observational Cohort Study (SPOCS; NCT03189875), investigating differences by baseline interferon gene signature (IFNGS) status.
47. Baseline features and functional outcomes in primary central nervous system vasculitis: development and validation of a prognostic model.
作者: Ahmad Nehme.;P N Sylaja.;Clothilde Isabel.;Jean Capron.;Caroline Arquizan.;Alexis Régent.;Benoit Guillon.;Nelly Dequatre.;Olivier Detante.;Barbara Casolla.;Michael Levraut.;Cédric Gollion.;Laurent Kremer.;Nicolas Lambert.;Laurent Derex.;Lisa Humbertjean.;Christian Denier.;Philippe Kerschen.;David Saadoun.;Stéphane Vannier.;Igor Sibon.;Adil Maarouf.;David Weisenburger-Lile.;Amina Sellimi.;Mikael Mazighi.;Sylvain Lanthier.;Alexandre Y Poppe.;Bertrand Mathon.;Grégoire Boulouis.;Sophie Godard.;Benjamin Terrier.;Achille Aouba.;Mathieu Zuber.;Soumya Sundaram.;Naveen Paramsivam.;Anais Briant.;Jean-Jacques Parienti.;Emmanuel Touzé.;Christian Pagnoux.;Hubert de Boysson.; .
来源: Rheumatology (Oxford). 2025年
Few data are available regarding the functional prognosis of adults with primary central nervous system vasculitis (PCNSV). We developed and validated a prognostic model for 12-month functional independence in adults with PCNSV.
48. Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in rheumatoid arthritis: the ANSWER cohort study.
作者: Yuhei Fujisawa.;Ryu Watanabe.;Tadashi Okano.;Akira Onishi.;Kosaku Murakami.;Kosuke Ebina.;Hirotaka Yamada.;Mai Yamashita.;Tohru Takeuchi.;Ayaka Yoshikawa.;Yonsu Son.;Hidehiko Makino.;Yuji Nozaki.;Tetsu Itami.;Wataru Yamamoto.;Yuya Yano.;Tasuku Togashi.;Masao Katsushima.;Kazuo Fukumoto.;Shinsuke Yamada.;Motomu Hashimoto.
来源: Rheumatology (Oxford). 2025年
This study aimed to compare drug retention rates according to the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with rheumatoid arthritis (RA) initiating biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).
49. Exosomal miR-132-3p derived from M1 macrophages mediates diffuse alveolar hemorrhage in systemic lupus erythematosus.
作者: Xun Chen.;Jun Xie.;Fuce Lu.;Qiongyan Li.;Guosheng Qiu.;Chunfeng Liang.
来源: Rheumatology (Oxford). 2025年
This study examines how exosomal miR-132-3p from M1 macrophages contributes to the development of systemic lupus erythematosus (SLE)-associated DAH and the molecular mechanisms involved.
50. The application of mNGS of bronchoalveolar lavage fluid in dissecting pulmonary infections in patients with CTD-ILD.
作者: Hang Yu.;Yanxiao Xu.;Die Chen.;Muxue Gong.;Wenjia Sun.;Mengdan Liu.;Ting Zhang.;Jing Xue.
来源: Rheumatology (Oxford). 2025年
To evaluate the application of metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) in the diagnosis of pulmonary infection in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD).
51. Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomised clinical trial.
作者: Sina Fadaei.;Matthijs S van der Leeuw.;Suzanne P Linn-Rasker.;Bo de Klerk.;Judith J W Peeters.;Debby den Uyl.;Annelies Maas-de Kok.;Reinhard Bos.;Janneke Tekstra.;Frank Nap.;Anne C A Marijnissen.;Paco M J Welsing.;Jaap M van Laar.
来源: Rheumatology (Oxford). 2025年
In rheumatoid arthritis (RA) patients with an insufficient response to conventional synthetic DMARDs (csDMARDs), both biological DMARDs and low-to-moderate dose glucocorticoids are effective treatment options. However, direct comparative evidence on their relative effectiveness and safety is lacking.
52. Interstitial lung disease in systemic lupus erythematosus: a 30-year population study.
作者: David M Ng.;Helen I Keen.;David B Preen.;Charles A Inderjeeth.;Johannes C Nossent.
来源: Rheumatology (Oxford). 2025年
To compare incidence, risk factors and outcomes for interstitial lung disease (ILD) between patients with systemic lupus erythematosus (SLE) and controls.
53. Novel serum autoantibodies against alpha thalassemia/mental retardation syndrome X-linked, a component of promyelocytic leukaemia nuclear bodies, in dermatomyositis.
作者: Yuta Yamashita.;Hiroyuki Kanoh.;Yoshinao Muro.;Satoshi Kamiya.;Eori Noda.;Norika Akashi.;Haruka Koizumi.;Mariko Ogawa-Momohara.;Takuya Takeichi.;Masashi Akiyama.
来源: Rheumatology (Oxford). 2025年 54. Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target.
作者: Takayuki Fujii.;Koichi Murata.;Shuichiro Nakabo.;Akira Onishi.;Kosaku Murakami.;Masao Tanaka.;Akio Morinobu.;Shuichi Matsuda.
来源: Rheumatology (Oxford). 2025年
While biologic or targeted synthetic DMARDs (b/tsDMARDs) improve mental status in RA patients with high disease activity, their effects after achieving low disease activity (LDA) or remission are unclear. We compared the effectiveness of b/tsDMARDs on mental status in RA patients who had reached treatment targets.
55. A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK.
作者: Charlotte E Gollins.;Annie Russell.;Theresa Smith.;Arani Vivekanantham.;Mel Brooke.;Laura C Coates.;Nicola Gullick.;Philip Helliwell.;Neil McHugh.;Caoimhe Fahy.;William Tillett.; .
来源: Rheumatology (Oxford). 2025年
Evidence evaluating effectiveness of biologic and targeted synthetic (b/ts) DMARDs in adults with PsA after exposure to ≥ 3 b/tsDMARDs is lacking. We aimed to evaluate response to sequential lines of b/tsDMARDs.
58. Chronic inflammatory burden on aortic valve disorders and atrioventricular block risk in spondyloarthritis: an ambispective cohort study.
作者: Hye Sang Park.;Ana Laiz.;Jesus Sánchez-Vega.;Lluis Sainz.;Carla Marco Pascual.;Anna López-Ferrer.;Asier Garcia Alija.;Albert Casals Urquiza.;Hector Corominas.
来源: Rheumatology (Oxford). 2025年
To assess the impact of chronic inflammatory burden on the risk of aortic valve outcomes and atrioventricular block (AVB) in spondyloarthritis (SpA).
59. Nailfold videocapillaroscopy abnormalities in autoimmune inflammatory myopathy subsets.
作者: Valérie Leclair.;Thaisa Cotton.;Hao Cheng Shen.;Claudie Berger.;Yves Troyanov.;Marie Hudson.;Geneviève Gyger.; .
来源: Rheumatology (Oxford). 2025年
Nailfold videocapillaroscopy (NVC) alterations have been described in autoimmune inflammatory myopathies (AIM). This study aimed to describe NVC abnormalities in AIM subsets using a clinico-sero-pathological approach.
|